Zenith Drugs Ltd

AI
Zenith Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Zenith Drugs Ltd

₹ 39.4 3.27%
23 Oct - close price
zenithdrugs.com NSE - SME: ZENITHDRUG
About

Incorporated in 2000, Zenith Drugs
Ltd is manufacturer of a range of
healthcare drugs and allied products[1]

Key Points

Business Overview:[1]
ZDL manufactures and markets
pharmaceutical products, including
a wide range of formulations in various
forms

Website NSE - SM
  • Market Cap ₹ 67.6 Cr.
  • Current Price ₹ 39.4
  • High / Low ₹ 65.2 / 33.3
  • Stock P/E 6.44
  • Book Value ₹ 36.3
  • Dividend Yield 0.00 %
  • ROCE 27.1 %
  • ROE 26.3 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Stock is trading at 1.09 times its book value
  • Company has a good return on equity (ROE) track record: 3 Years ROE 27.6%

Cons

  • Company has high debtors of 188 days.
  • Working capital days have increased from 55.6 days to 112 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of Nifty SME Emerge

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024
92 114 131
85 104 114
Operating Profit 7 9 17
OPM % 8% 8% 13%
1 1 1
Interest 2 2 3
Depreciation 1 1 1
Profit before tax 4 7 13
Tax % 29% 27% 28%
3 5 10
EPS in Rs 5.59
Dividend Payout % -0% -0% 9%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 15%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 115%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -39%
Return on Equity
10 Years: %
5 Years: %
3 Years: 28%
Last Year: 26%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024
Equity Capital 0.40 0.40 17
Reserves 12 17 45
19 26 25
38 54 48
Total Liabilities 69 98 135
10 12 11
CWIP 3 -0 4
Investments -0 -0 -0
55 86 120
Total Assets 69 98 135

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024
5 -5 -13
-5 -0 26
1 5 -4
Net Cash Flow 1 -0 9
Free Cash Flow -0 -10 -18
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 93% -32% -53%

Ratios

Consolidated / View Standalone

Mar 2022 Mar 2023 Mar 2024
Debtor Days 128 159 188
Inventory Days 96 192 249
Days Payable 274 413 412
Cash Conversion Cycle -50 -62 25
Working Capital Days 16 39 112
ROCE % 24% 27%

Insights

In beta
Mar 2024 Mar 2025 Mar 2026
Foreign Exchange Earnings from Exports
INR Lakhs ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Permanent Employees
count ・Standalone data
Number of Molecules
count ・Standalone data
Number of SKUs
count ・Standalone data
Revenue Share - Capsules
% ・Standalone data
Revenue Share - Liquid Externals
% ・Standalone data
Revenue Share - Ointments/Creams
% ・Standalone data
Revenue Share - Oral Powders
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

4 Recently
Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026Sep 2026
69.98% 69.98% 69.98% 69.98% 69.98% 69.98%
5.81% 0.42% 0.06% 0.00% 0.00% 0.00%
1.93% 0.00% 0.00% 0.00% 0.00% 0.00%
22.28% 29.60% 29.96% 30.02% 30.02% 30.02%
No. of Shareholders 1,1171,3551,5441,4661,4351,317

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings